

Donald J L Jones

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/757873/publications.pdf>

Version: 2024-02-01

72
papers

3,270
citations

236925

25
h-index

149698

56
g-index

72
all docs

72
docs citations

72
times ranked

5166
citing authors

#	ARTICLE	IF	CITATIONS
1	Nonadherence in Hypertension: How to Develop and Implement Chemical Adherence Testing. Hypertension, 2022, 79, 12-23.	2.7	51
2	Determination of N ⁷ -glycidamide guanine adducts in human blood DNA following exposure to dietary acrylamide using liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2022, 36, e9245.	1.5	6
3	Increased mitochondrial proline metabolism sustains proliferation and survival of colorectal cancer cells. PLoS ONE, 2022, 17, e0262364.	2.5	12
4	Modulation of acetylcholinesterase activity using molecularly imprinted polymer nanoparticles. Journal of Materials Chemistry B, 2022, 10, 6732-6741.	5.8	7
5	Molecular imprinting as a tool for determining molecular markers: a lung cancer case. RSC Advances, 2022, 12, 17747-17754.	3.6	3
6	Proteomic Characterization of Circulating Molecular Perturbations Associated With Pancreatic Adenocarcinoma Following Intravenous 1% Fatty Acid and Gemcitabine Administration: A Pilot Study. Journal of Parenteral and Enteral Nutrition, 2021, 45, 738-750.	2.6	1
7	Association of gut-related metabolites with outcome in acute heart failure. American Heart Journal, 2021, 234, 71-80.	2.7	25
8	Cov-MS: A Community-Based Template Assay for Mass-Spectrometry-Based Protein Detection in SARS-CoV-2 Patients. JACS Au, 2021, 1, 750-765.	7.9	29
9	Mass spectrometric detection of KRAS protein mutations using molecular imprinting. Nanoscale, 2021, 13, 20401-20411.	5.6	8
10	Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets. European Journal of Heart Failure, 2020, 22, 70-80.	7.1	28
11	The measurement of KRAS G12 mutants using multiplexed selected reaction monitoring and ion mobility mass spectrometry. Rapid Communications in Mass Spectrometry, 2020, 34, e8657.	1.5	4
12	Dealing with complexity: general discussion. Faraday Discussions, 2019, 218, 138-156.	3.2	1
13	High resolution techniques: general discussion. Faraday Discussions, 2019, 218, 247-267.	3.2	4
14	Data mining and visualisation: general discussion. Faraday Discussions, 2019, 218, 354-371.	3.2	2
15	Proenkephalin and prognosis in heart failure with preserved ejection fraction: a GREAT network study. Clinical Research in Cardiology, 2019, 108, 940-949.	3.3	12
16	Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure: results from BIOSTAT-CHF. European Journal of Heart Failure, 2019, 21, 877-886.	7.1	68
17	Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failure. European Journal of Heart Failure, 2018, 20, 260-267.	7.1	30
18	Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. Clinical Proteomics, 2018, 15, 35.	2.1	6

#	ARTICLE	IF	CITATIONS
19	In Reply. <i>Clinical Chemistry</i> , 2017, 63, 1046-1047.	3.2	0
20	Trimethylamine N-oxide and Risk Stratification after Acute Myocardial Infarction. <i>Clinical Chemistry</i> , 2017, 63, 420-428.	3.2	120
21	Proenkephalin, Renal Dysfunction, and Prognosis in Patients With Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 56-69.	2.8	66
22	Mass spectrometry in medicine: a technology for the future?. <i>Future Science OA</i> , 2017, 3, FSO213.	1.9	16
23	Plasma growth hormone is a strong predictor of risk at 1 year in acute heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 281-289.	7.1	12
24	Enrichment of Thrombin Activatable Fibrinolysis Inhibitor (TAFI), A Novel Pro-Thrombotic Protein in Lipoproteins of South Asian Patients with Coronary Artery Disease. <i>Heart</i> , 2016, 102, A125.2-A125.	2.9	0
25	Advances in quadrupole and time-of-flight mass spectrometry for peptide MRM based translational research analysis. <i>Proteomics</i> , 2016, 16, 2206-2220.	2.2	16
26	High mass accuracy assay for trimethylamine N-oxide using stable-isotope dilution with liquid chromatography coupled to orthogonal acceleration time of flight mass spectrometry with multiple reaction monitoring. <i>Analytical and Bioanalytical Chemistry</i> , 2016, 408, 797-804.	3.7	33
27	Trimethylamine N-oxide and prognosis in acute heart failure. <i>Heart</i> , 2016, 102, 841-848.	2.9	195
28	Proteomics of human plasma in diastolic heart failure (DHF) using novel chemical affinity, mixed mode matrix (M3). <i>Heart</i> , 2015, 101, A7.1-A7.	2.9	0
29	Search for novel circulating cancer chemopreventive biomarkers of dietary rice bran intervention in Apc ^{Min} mice model of colorectal carcinogenesis, using proteomic and metabolic profiling strategies. <i>Molecular Nutrition and Food Research</i> , 2015, 59, 1827-1836.	3.3	13
30	High definition lipoproteomics reveal dysregulated redox proteins in coronary artery disease. <i>Heart</i> , 2015, 101, A9.1-A9.	2.9	0
31	The use of turbulent flow chromatography for rapid, on-line analysis of tryptic digests. <i>Rapid Communications in Mass Spectrometry</i> , 2015, 29, 2140-2146.	1.5	0
32	Growth hormone for risk stratification and effects of therapy in acute myocardial infarction. <i>Biomarkers</i> , 2015, 20, 371-375.	1.9	2
33	Pleiotropic effects of statins in hypercholesterolaemia: a prospective observational study using a lipoproteomic based approach. <i>Lancet, The</i> , 2015, 385, S21.	13.7	19
34	Identification of novel biomarkers in plasma for prediction of treatment response in patients with heart failure. <i>Lancet, The</i> , 2015, 385, S26.	13.7	23
35	Separation and fragmentation study of isocoproprophyrin derivatives by UHPLC-ESI-exact mass MS/MS and identification of a new isocoproprophyrin sulfonic acid metabolite. <i>Journal of Mass Spectrometry</i> , 2014, 49, 80-85.	1.6	2
36	Assessment of reproducibility in depletion and enrichment workflows for plasma proteomics using label-free quantitative data independent LC-MS. <i>Proteomics</i> , 2014, 14, 4-13.	2.2	30

#	ARTICLE	IF	CITATIONS
37	Novel biomarkers for prediction of poor treatment response in heart failure to guide therapy. <i>Lancet, The</i> , 2014, 383, S32.	13.7	1
38	Proenkephalin and Prognosis After Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2014, 63, 280-289.	2.8	56
39	Improved analysis of vitamin D metabolites in plasma using liquid chromatography tandem mass spectrometry, and its application to cardiovascular research. <i>Biomedical Chromatography</i> , 2014, 28, 913-917.	1.7	8
40	Pro-Substance P for Evaluation of Risk in Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1698-1707.	2.8	17
41	Qualitative and Quantitative Characterization of Plasma Proteins When Incorporating Traveling Wave Ion Mobility into a Liquid Chromatography-Mass Spectrometry Workflow for Biomarker Discovery: Use of Product Ion Quantitation As an Alternative Data Analysis Tool for Label Free Quantitation. <i>Analytical Chemistry</i> , 2014, 86, 1972-1979.	6.5	21
42	52...Discovering New Biomarkers for Predicting Treatment Response in Heart Failure Using Plasma Proteomics. <i>Heart</i> , 2014, 100, A30.1-A30.	2.9	0
43	Liquid chromatography-tandem mass spectrometry of porphyrins and porphyrinogens in biological materials: separation and identification of interfering poly(ethylene) glycol by travelling wave ion mobility spectrometry/tandem mass spectrometry. <i>Biomedical Chromatography</i> , 2013, 27, 1782-1787.	1.7	3
44	Vitamin D and prognosis in acute myocardial infarction. <i>International Journal of Cardiology</i> , 2013, 168, 2341-2346.	1.7	70
45	Prolonged Biologically Active Colonic Tissue Levels of Curcumin Achieved After Oral Administration: A Clinical Pilot Study Including Assessment of Patient Acceptability. <i>Cancer Prevention Research</i> , 2013, 6, 119-128.	1.5	89
46	Ultra high-performance liquid chromatography of porphyrins. <i>Biomedical Chromatography</i> , 2012, 26, 331-337.	1.7	12
47	The uroguanylin system and human disease. <i>Clinical Science</i> , 2012, 123, 659-668.	4.3	13
48	Notch3 and Hey-1 as Prognostic Biomarkers in Pancreatic Adenocarcinoma. <i>PLoS ONE</i> , 2012, 7, e51119.	2.5	62
49	Travelling wave ion mobility mass spectrometry of 5-aminolaevulinic acid, porphobilinogen and porphyrins. <i>Rapid Communications in Mass Spectrometry</i> , 2012, 26, 480-486.	1.5	15
50	Ultra high-performance liquid chromatography of porphyrins in clinical materials: column and mobile phase selection and optimisation. <i>Biomedical Chromatography</i> , 2012, 26, 714-719.	1.7	19
51	Tissue distribution and metabolism of the putative cancer chemopreventive agent 3,4,5-trimethoxyflavonol (TMFol) in mice. <i>Biomedical Chromatography</i> , 2012, 26, 1559-1566.	1.7	5
52	Porphyrinogen fragmentation profiles by ultra-high-performance liquid chromatography/electrospray ionisation tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2011, 25, 3749-3757.	1.5	5
53	Curcumin ameliorates oxaliplatin-induced chemoresistance in HCT116 colorectal cancer cells <i>in vitro</i> and <i>in vivo</i> . <i>International Journal of Cancer</i> , 2011, 129, 476-486.	5.1	77
54	Clinical Pharmacology of Resveratrol and Its Metabolites in Colorectal Cancer Patients. <i>Cancer Research</i> , 2010, 70, 7392-7399.	0.9	511

#	ARTICLE	IF	CITATIONS
55	Plasma metabolic profiling reveals age-dependency of systemic effects of green tea polyphenols in mice with and without prostate cancer. <i>Molecular BioSystems</i> , 2010, 6, 1911.	2.9	5
56	Dose-Response Relationships for N7-(2-Hydroxyethyl)Guanine Induced by Low-Dose [¹⁴ C]Ethylene Oxide: Evidence for a Novel Mechanism of Endogenous Adduct Formation. <i>Cancer Research</i> , 2009, 69, 3052-3059.	0.9	34
57	Mutagenicity of DNA adducts derived from ethylene oxide exposure in the pSP189 shuttle vector replicated in human Ad293 cells. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2009, 678, 129-137.	1.7	26
58	Simultaneous detection of five different 2- ^{hydroxyethyl} -DNA adducts formed by ethylene oxide exposure, using a high-performance liquid chromatography/electrospray ionisation tandem mass spectrometry assay. <i>Rapid Communications in Mass Spectrometry</i> , 2008, 22, 19-28.	1.5	25
59	Metabolic profiling of transgenic adenocarcinoma of mouse prostate (TRAMP) Tissue by ¹ H-NMR analysis: evidence for unusual phospholipid metabolism. <i>Prostate</i> , 2008, 68, 1035-1047.	2.3	32
60	Improving the Diagnostic Accuracy of N-Terminal B-Type Natriuretic Peptide in Human Systolic Heart Failure by Plasma Profiling Using Mass Spectrometry. <i>Journal of Proteome Research</i> , 2007, 6, 3329-3334.	3.7	5
61	Determination of Endogenous and Exogenously Derived N7-(2-Hydroxyethyl)guanine Adducts in Ethylene Oxide-Treated Rats. <i>Chemical Research in Toxicology</i> , 2007, 20, 290-299.	3.3	35
62	Searching for biomarkers of heart failure in the mass spectra of blood plasma. <i>Proteomics</i> , 2006, 6, 5903-5914.	2.2	18
63	Development of a novel site-specific mutagenesis assay using MALDI-ToF MS (SSMA-MS). <i>Nucleic Acids Research</i> , 2006, 34, e150-e150.	14.5	4
64	A synthetic approach to the generation of quercetin sulfates and the detection of quercetin 3-O-sulfate as a urinary metabolite in the rat. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 6727-6731.	3.0	27
65	DNA adducts: Mass spectrometry methods and future prospects. <i>Toxicology and Applied Pharmacology</i> , 2005, 207, 293-301.	2.8	99
66	The Human Apoptosis-inducing Protein AMID Is an Oxidoreductase with a Modified Flavin Cofactor and DNA Binding Activity. <i>Journal of Biological Chemistry</i> , 2005, 280, 30735-30740.	3.4	82
67	Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 120-5.	2.5	173
68	Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4-tetramethoxystilbene. <i>British Journal of Cancer</i> , 2004, 90, 736-744.	6.4	231
69	Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. <i>British Journal of Cancer</i> , 2004, 90, 1011-1015.	6.4	387
70	Characterisation of metabolites of the putative cancer chemopreventive agent quercetin and their effect on cyclo-oxygenase activity. <i>British Journal of Cancer</i> , 2004, 91, 1213-1219.	6.4	40
71	Identification and Characterization of (3- ^{hydroxyethyl} ,4- ^{hydroxyethyl} -Dihydroxy)-1,N ² -benzetheno-2-deoxyguanosine 3-Monophosphate, a Novel DNA Adduct Formed by Benzene Metabolites. <i>Chemical Research in Toxicology</i> , 2002, 15, 1088-1095.	3.3	25
72	Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2002, 11, 105-11.	2.5	194